NASDAQ:FWPForward Pharma A/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Forward Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.95 -0.06 (-1.00 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$5.85Now: $5.95▼$6.1150-Day Range$5.75MA: $6.55▼$7.5552-Week Range$4.61Now: $5.95▼$12.72Volume56,300 shsAverage Volume100,728 shsMarket Capitalization$40.40 millionP/E RatioN/ADividend YieldN/ABeta2.03 ProfileAdvanced ChartCompetitorsDividendEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Forward Pharma A/S operates as a biopharmaceutical company. The company focuses on developing FP187, a proprietary formulation of dimethyl fumarate used for the treatment of various inflammatory and neurological indications. Forward Pharma A/S was founded in 2005 and is headquartered in Copenhagen, Denmark.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Forward Pharma A/S. Previous Next 2.8 Community Rank Outperform VotesForward Pharma A/S has received 274 “outperform” votes. (Add your “outperform” vote.)Underperform VotesForward Pharma A/S has received 213 “underperform” votes. (Add your “underperform” vote.)Community SentimentForward Pharma A/S has received 56.26% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Forward Pharma A/S and other stocks. Vote “Outperform” if you believe FWP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FWP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldForward Pharma A/S does not currently pay a dividend.Dividend GrowthForward Pharma A/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Forward Pharma A/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 19.39% of the stock of Forward Pharma A/S is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioForward Pharma A/S has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.69 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FWP Previous Symbol CUSIPN/A CIK1604924 Webwww.forward-pharma.com Phone0114533444242Debt Debt-to-Equity RatioN/A Current Ratio131.15 Quick Ratio131.15Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.25 billion Price / Sales0.03 Cash FlowN/A Price / Cash FlowN/A Book Value$11.42 per share Price / Book0.52Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees5 Outstanding Shares6,790,000Market Cap$40.40 million Next Earnings DateN/A OptionableNot Optionable NASDAQ:FWP Rates by TradingView Receive FWP News and Ratings via Email Sign-up to receive the latest news and ratings for FWP and its competitors with MarketBeat's FREE daily newsletter. Forward Pharma A/S (NASDAQ:FWP) Frequently Asked Questions How has Forward Pharma A/S's stock been impacted by COVID-19 (Coronavirus)? Forward Pharma A/S's stock was trading at $5.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FWP shares have increased by 7.2% and is now trading at $5.95. View which stocks have been most impacted by Coronavirus. How were Forward Pharma A/S's earnings last quarter? Forward Pharma A/S (NASDAQ:FWP) announced its quarterly earnings data on Thursday, September, 1st. The biotechnology company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.06. View Forward Pharma A/S's earnings history. Has Forward Pharma A/S been receiving favorable news coverage? Media headlines about FWP stock have been trending extremely positive on Monday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Forward Pharma A/S earned a coverage optimism score of 5.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutForward Pharma A/S. Who are some of Forward Pharma A/S's key competitors? Some companies that are related to Forward Pharma A/S include Newron Pharmaceuticals (NWPHF), CELYAD SA/ADR (CYAD), Sol Gel Technologies (SLGL), Evolus (EOLS), Immunic (IMUX), Arbutus Biopharma (ABUS), Rockwell Medical (RMTI), Aldeyra Therapeutics (ALDX), BIOFRONTERA AG/ADR (BFRA), Sierra Oncology (SRRA), Minerva Neurosciences (NERV), Endonovo Therapeutics (ENDV), Conatus Pharmaceuticals (CNAT), Humanigen (HGEN) and Evelo Biosciences (EVLO). View all competitors. What other stocks do shareholders of Forward Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Forward Pharma A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), TherapeuticsMD (TXMD), Celldex Therapeutics (CLDX), Fate Therapeutics (FATE) and MOTIF BIO PLC/S (MTFB). Who are Forward Pharma A/S's key executives? Forward Pharma A/S's management team includes the following people: Mr. Florian Schonharting, Co-Founder & Chairman (Age 50)Dr. Claus Bo Svendsen, CEO & Principal Financial Officer (Age 42)Mr. Thomas Carbone, Principal Accounting Officer (Age 62) What is Forward Pharma A/S's stock symbol? Forward Pharma A/S trades on the NASDAQ under the ticker symbol "FWP." Who are Forward Pharma A/S's major shareholders? Forward Pharma A/S's stock is owned by many different retail and institutional investors. Top institutional investors include Morgan Stanley (0.71%). Which major investors are buying Forward Pharma A/S stock? FWP stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley. How do I buy shares of Forward Pharma A/S? Shares of FWP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Forward Pharma A/S's stock price today? One share of FWP stock can currently be purchased for approximately $5.95. How big of a company is Forward Pharma A/S? Forward Pharma A/S has a market capitalization of $40.40 million and generates $1.25 billion in revenue each year. Forward Pharma A/S employs 5 workers across the globe. What is Forward Pharma A/S's official website? The official website for Forward Pharma A/S is www.forward-pharma.com. How can I contact Forward Pharma A/S? Forward Pharma A/S's mailing address is OSTERGADE 24A 1, COPENHAGEN G7, 1100. The biotechnology company can be reached via phone at 0114533444242 or via email at [email protected] This page was last updated on 6/1/2020 by MarketBeat.com Staff
